Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Package Insert Revision for Bisphosphonates
November 11, 2011
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
- 1st PAFSC Committee Recommends Approval for Products Including Eisai’s Lunesta
November 8, 2011
- MHLW Announces Additional Indications for 3 APIs Following Prior Assessments
November 7, 2011
- CSIMC Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 4, 2011
- CSIMC Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 4, 2011
- Japan, China, S. Korea Agree to Draft GL on Joint Clinical Trials
November 2, 2011
- Chuikyo Subcommittee Approves Proposal to Expand Range of Drugs Subject to Re-pricing
November 2, 2011
- Chuikyo Approves Plan to Ban Use of “Dispensing Point” Cards by Pharmacies, Drugstores
November 2, 2011
- Committee Recommends Approval of 3 Products Including MSD’s Rota Teq
November 1, 2011
- Business Sector Call for Japan to Join TPP Talks Voiced at National Strategy Council Meeting
November 1, 2011
- Korosho to Ask Doctors to Exercise Caution in Co-prescribing 3 or More Psychotropics
November 1, 2011
- Healthcare Reps at Chuikyo Call For Quality Assurance to Promote GE Use
November 1, 2011
- WT of DPJ Begins Discussion, Not Yet Known If It Covers Drug Pricing System
October 31, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…